ClinicalTrials.gg
CompletedNCT03110861Updated Sep 4, 2025

Pulsta® Transcatheter Pulmonary Valve Korean Multicenter Study

An interventional study of Pulsta® Transcatheter Pulmonary Valve (TPV) Replacement in Congenital Heart Defect, Pulmonary Valve; Insufficiency, Congenital and Pulmonary Valve Stenosis, sponsored by Taewoong Medical Co., Ltd.. Completed at 5 sites in South Korea. Open to participants aged 10 Years and older. Per ClinicalTrials.gov, last updated 2025-09-04.

Sponsored by Taewoong Medical Co., Ltd. (part of Olympus Corporation) · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
10 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Heart Defects, Congenital with a site in Korea, Republic of — 2 open to participants now, 2 under way, none of them phase 3. Heart Defects, Congenital · Korea, Republic of.

Started
2017
with 1 other
No phase
8 of 17
2 open now
Registered
8th of 17
by date
Lead sponsor
1 of 17
Taewoong Medical Co., Ltd.

Among the 17 studies in Heart Defects, Congenital with a site in Korea, Republic of, this one is one of 2 that started in 2017, is one of 8 with no phase, and was the 8th registered.

Heart Defects, Congenital

992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.

Browse Heart Defects, Congenital studies →

Open to participants now

2 of the 17 studies in Heart Defects, Congenital with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.

This study: 10 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Heart Defects, Congenital with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and effectiveness of the TPV in patients with pulmonary valve dysfunction.

Read the detailed description

The TPV is indicated for use in patients with previous undergone replacement of bioprosthetic valve or conduit due to either pulmonary valve atresia, stenosis, regurgitation or a combination of them and present with dysfunctional right ventricular ourflow tract (RVOT) requiring treatment for severe pulmonary regurgitation and/or RVOT conduit obstruction. Consecutive subject data should be collected at discharge, 1, 3, 6 month, and 1-5 years post TPV implantation.

03

Conditions studied

  • Congenital Heart Defect
  • Pulmonary Valve; Insufficiency, Congenital
  • Pulmonary Valve Stenosis
04

Who can participate

Ages eligible
10 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight greater than or equal to 30 kilograms
  • Pulmonary regurgitation ≥moderate pulmonary regurgitation (PR) (≥3+) or RVOT conduit obstruction with mean gradient >35mmHg by echocardiography
  • pulmonary artery annulus or in situ conduit size of ≥16 and ≤26mm
  • Patient willing to provide written and comply with follow-up requirements

Exclusion criteria

Exclusion Criteria:

  • Pre-existing mechanical heart valve in any position
  • Obstruction of the central veins (pulmonic bioprosthesis delivery system to the heart)
  • Coronary artery compression
  • A known to Aspirin or Heparin
  • disease
  • Active infectious disease (e.g. endocarditis, meningitis)
  • Estimated survival less than 6 months
  • Female of who are unable to take adequate precautions, are known to be pregnant, or are currently breastfeeding an infant.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Pulsta® Transcatheter Pulmonary Valve

    Pulsta® Transcatheter Pulmonary Valve (TaeWoong Medical Co., Ltd. Korea)

    Device: Pulsta® Transcatheter Pulmonary Valve (TPV) Replacement

Interventions

  • DevicePulsta® Transcatheter Pulmonary Valve (TPV) Replacement

    Pulsta® Transcatheter Pulmonary Valve Replacement

06

What researchers measure

Primary outcomes

  1. Hemodynamic functional improvement at 6month

    Hemodynamic functional improvement is defined as mean RVOT gradient ≤30 mmHg by continuous wave doppler, and a pulmonary regurgitant fraction \<20% by cardiac magnetic resonance (MR).

    Time frame: 6 months

  2. Procedural / Device related serious adverse events at 6month

    Time frame: 6 months

Secondary outcomes

  1. Procedural success

    Procedural success is defined as the TPV implant within desired position, Right ventricle-Pulmonary artery (RV-PA) peak systolic pressure gradient \<35mmHg by catheter, less mild pulmonary regurgitation by angiography, and freedom from explantation of the TPV at 24 hours post-implant.

    Time frame: 5 days

  2. Hemodynamic function

    Hemodynamic function will be measured including peak RVOT pressure gradient, mean RVOT pressure gradient, RV-PA pressure gradient, RV pressure, cardiac output, cardiac index, RV end-diastolic volume by echocardiography, cardiac MR, or catheterization.

    Time frame: 5 years

  3. Severity of pulmonary regurgitation

    Time frame: 5 years

  4. New York Heart Association (NYHA) functional classification

    Time frame: 5 years

  5. Stent fracture

    Stent fracture will be assessed by the investigator through radiography (X-ray, Fluoroscopy).

    Time frame: 5 years

  6. Catheter reintervention on TPV

    Time frame: 5 years

  7. Reoperation

    Time frame: 5 years

  8. Procedural / Device related serious adverse events

    Time frame: 5 years

  9. Death (all cause / procedural / device-related)

    Time frame: 5 years

  10. Other adverse events

    Time frame: 5 years

  11. Pulmonary regurgitant fraction

    Pulmonary regurgitant fraction will be measured by cardiac MRI.

    Time frame: 6 months

07

Study locations

5 sites
  • Seoul National University Hospital
    Seoul, Haehak-ro Jongno-gu 03080, South Korea
  • Sejong General Hospital
    Bucheon-si, Hohyun-ro, Sosa-gu 14754, South Korea
  • Samsung Medical Center
    Seoul, Ilwon-ro, Gangnam-gu 06351, South Korea
  • Asan Medical Center
    Seoul, Olympic-ro, Songpa-gu 05505, South Korea
  • Severance Hospital
    Seoul, Yonsei-ro, Seodaemun-gu 03722, South Korea
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Nov 2019, 31 months.

Of 226 interventional studies with no phase under Heart Defects, Congenital, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 57. This study's 31 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2017
First posted
Apr 12, 2017
StartActual
Mar 22, 2017
Primary completionActual
Nov 6, 2019
CompletionActual
Jul 12, 2024
Last update
Sep 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03110861
Responsible party
Sponsor
First posted
Apr 12, 2017
Start date
Mar 22, 2017
Primary completion
Nov 6, 2019
Completion
Jul 12, 2024
Last update
Sep 4, 2025

Study contacts

Gi Beom Kim, phD. MD.
study chair · Seoul National University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion